A VA research team has documented the personal values that women veterans express when beginning treatment for obstructive ...

IntroductionHello everyone. I am Bonno.Are you familiar with the ancient Greek word "Pharmakon"? It is the etymological root of the modern English word "Pharmacy," and it refers to something that ...

Therapy with GLP-1 RAs reduces the frequency of apnea and hypopnea events in obesity, serving as an effective adjunct to ...

U.S. adults have sleep apnea, but many remain undiagnosed, often misattributing symptoms like fatigue and snoring.

ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit ...

How big is the respiratory care devices market, and what is driving its growth? The global respiratory care devices market is ...

Looking back on medical devices & supplies - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst ...

A 2019 analysis published in The Lancet Respiratory Medicine estimated that approximately 936 million adults aged 30 to 69 worldwide have OSA. Through technology, education, provider partnerships and ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - ...

I am protected by a diagnosis. Thousands of Massachusetts residents now face losing access. The state's Group Insurance ...

An opinion piece argues that ending Medi-Cal coverage for GLP-1 medications could shift costs toward treating obesity-related ...

Ending coverage does not merely stop progress. It reverses it—and costs may return as diabetes, CPAP equipment, additional medications, disability, and hospital care.